Table 7 Histopathologic findings in COVID and non-COVID patients
From: The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?
Histopathology | Non-COVID group | COVID group |
|---|---|---|
Acute cholecystitis | 899 (47.8%) | 58 (43%) |
Chronic cholecystitis | 489 (26%) | 18 (13.3%) |
Cholecystitis with necrosis/gangrene | 419 (22.3%) | 55 (40.7%) |
Acute on chronic cholecystitis | 46 (2.4%) | 1 (0.7%) |
Perforated cholecystitis/abscess formation | 11(0.6%) | 2 (0.15%) |
Malignancy | 10 (0.5%) | 1 (0.7%) |
Hydrocele | 2 (0.11%) | 0 (0%) |
Adenosis | 2 (0.11%) | 0 (0%) |
Normal | 1 (0.05%) | 0 (0%) |
Total | 1879 (100%) | 135 (100%) |